Pap smear, Pap test, Cervical cancer, Cervical cancer screening, BioSciCon, the Biomedical Science Consulting Company, Inc.

   

About Us
Products
Image Gallery
News
Publications
Consulting
licensing
GAWH
Helpful Links
Contact Us
Home Page

Our Companies

Biomedical Science Consulting Company, BioSciCon, Inc., is a woman-owned, small business start-up biotechnology company focused on R&D of the proprietary MarkPap® technology. BioSciCon has recently organized a Consortium of business companies to commercialize the MarkPap® technology as new products emerging from the R&D component after translational research from prototypes to products. The other members of this Consortium are MarkPap LLC, MarkPap Pacific, LLC and MarkPap India, LLC.

In 2007, BioSciCon sponsored the creation of The Global Academy for Women's Health, Inc., independent non-profit organization which integrated the multiple prior non-profit activities of BioSciCon's founders continuing their legacy to work for public benefit improving women's health and saving women's lives.

All companies are located in Rockville, MD. BioSciCon headquarters are at Forest Landing Circle, Rockville, MD. Another BioSciCon' facility is at the Johns Hopkins University, Montgomery County Campus, Rockville, MD. MarkPap Pacific LLC and MarkPap India, LLC are located at the Shady Grove Innovation Center in Rockville, MD. The Global Academy for Women's Health, Inc is located at the John's Hopkins University, Montgomery County Campus in Rockville, MD. Please see Contact Us page for details.

Our Mission

The primary mission of BioSciCon, Inc. is to bring the new MarkPap® Technology products to public benefit and save women's lives around the world. The primary function of MarkPap LLC is to commercialize proprietary MarkPap® Technology products after completion of the translational research, and to provide resources for further financing of R&D

Who We Are

Olivera Markovic, M.D., Ph.D is Founding Director of BioSciCon, Inc. and President of the Global Academy for Women’s Health, Inc. She is also Senior Vice President and Chief Scientific Officer of MarkPap LLC. and MarkPap Pacific, LLC and MarkPap India, LLC.
Dr. Olivera Markovic is a cancer research scientist, entrepreneur academician and author.
Dr. Markovic is an accomplished cancer research scientist with more than 200 scientific publications including books, chapters, invited review articles and patents. She has been a principal investigator and program director of research projects funded by the NIH, industry, universities and private foundations. She has been Director of clinical laboratories, research laboratories and Head of research departments at universities.
Dr. Markovic has 17 years entrepreneurial experience being founder, director and manager of small business companies and a non-profit organization. She was trained in marketing and commercialization through NIH organized Commercialization Assistance Programs (two years), and at SCORE/SBA, Washington DC. Together with Dr. Nenad Markovic and BioSciCon, she received SCORE Client of the Year Award in 2005. Dr. Olivera Markovic is an experienced academician, professor at five universities/medical schools, teaching thousands of students for more than 30 years from undergraduate, graduate and postgraduate levels, including residents. She taught basic medical science courses (biochemistry, physiology, anatomy, pathophysiology, clinical chemistry) at medical schools. At universities, she taught science courses (chemistry, biology, biochemistry, anatomy, physiology) and health courses (women’s health, drug use and abuse, personal and community health, strategies in stress release).
Featured in bibliographical records of Marquis Who's Who in the World, Who's Who in America, Who's Who in Science and Engineering, Who's Who in Medicine and Healthcare and Who's Who of American Women. She was selected among 2000 Outstanding People of the 20th Century by the International Bibliographical Centre, Cambridge, England.

Nenad Markovic, M.D., Ph.D is founder and President of BioSciCon, Inc, MarkPap LLC, MarkPap Pacific, LLC and MarkPap India. LLC.
Dr. Nenad Markovic is a medical doctor (internist, hematologist, oncologist), entrepreneur, scientist, academician and author.
The reason why this high ranking academician (chair of oncology, full professor of medicine and hematology, professor of laboratory medicine and clinical pharmacology at five medical schools), successful medical doctor (head, chief and director of clinical units and departments), recipient of many recognitions and awards for excellence in medicine and allied sciences, and renown scientist (author of four books and over 200 scientific papers, trained and participated in the medical programs at NIH and FDA), has decided to become an entrepreneur was the discovery made by him and Dr. Olivera Markovic. This was a new bioactive protein residing only in specimens obtained from abnormal cervical tissues, and the success of his team of scientists to develop a proprietary technology for visualization of this protein by simple laboratory pathology means. The idea was conceived in 1987, the small business company formed in 1996, preclinical studies completed to enable the issuance of the US patent for a new product covering the protein, the methods for its visualization and the application – clinical use as an in vitro diagnostic test. Since this time, he planned a long term translational research to develop pipeline of products which, based on the original principles, will help millions of women in need for protection against a grave disease, cervical cancer. Dr. Markovic has also regulatory experience as former FDA medical reviewer and current HRSA reviewer.
Recently, together with Dr. Olivera Markovic, authored the book "What Every Woman Should Know about Cervical Cancer" that was published by Springer in 2008.
His biography is featured in several world-wide bibliographical editions.

Oleg Panashchenko, Ph.D. is Chief Information Technology Officer-consultant at MarkPap Pacific, LLC. He holds MS degree in Physics and PhD degree in Optical Physics from Moscow Institute of Physics and Technology. Dr. Panashchenko is bringing to the Company his exceptional talents and vast experience in comprehensive software development and information technology experience. He successfully served before in all aspects of software development life-cycle including design, development, implementation and support for Java/J2EE, C++ and mixed language systems for standard, web-based and enterprise-level applications. Prior to joining MarkPap Pacific, Dr. Panashchenko worked for USPTO, Lockheed Martin, Tachyon Networks Planet Exchange, Inc, International Land Systems, Inc, in the US and Tavex and Lucky Net, Kiev, Ukraine.

BioSciCon Cervical Cancer Study Group is a multidisciplinary research group consisting of medical doctors (general practitioners, gynecologists, oncologists and pathologists) from BioSciCon's Clinical and Laboratory Research Sites, and oncologists, biomedical scientists, statisticians, chemists, physicists, computer scientists, and experts in other disciplines affiliated with this program who participate in the BioSciCon's Research Site. Currently active members of the group are highlighted with asterisk. This is a dynamic group of professional teams that are perpetually changing depending on actual programs. Nenad Markovic, MD, PhD* (Research Center), Olivera Markovic, MD, PhD* (Research Center), Lewis Townsend, MD* (Clinical Site), William Smith, MD* (Laboratory Site), James Sundeen, MD (Laboratory Site), David Hankins, PhD (Laboratory Site), Vladan Posarac, MD (Research Center), Mr. Stephen McJonathan* (Microscopy/Imaging), Oleg Panashchenko, PhD* (optical physicist and computer scientist, Research Center), Mr. Derrick Miller (IT/Web), Gary Peck, MD* (Scientific Consultant), Edward Henderson, MD* (Scientific Consultant), S. Kati, PhD (statistician, Research Center), Ing. Marjan Cotic* (IT Consultant), Ing. Cvetan Saljinski* (Imaging/Photography Consultant), Shelly Parr, MD (Clinical Site), Jonathan Cosin, MD (Clinical Site), MIlena Simic (Research Center), Allan Ross, MD (Clinical Site), Venkat Iyer, MD (Clinical Site, India), Pravina Santwani, MD* (Clinical Site, India), Savita Shettar, MD* (Clinical Site, India), Zhenchang Xu (Clinical Site, China), Kalayani Dukipati (Clinical Site, India). Members of this group serve on the Scientific Board per a particular program. Dr. Olivera Markovic coordinates Scientific Board activities.

Business Advisory Team. Business Support Counselors to Small Businesses, Chapter 1, Washington, DC provide continuous business support through Ms. Ann Dobbs and other counselors from the Chapter contributing with their particular expertise. BioSciCon, Inc was SCORE Client of the Year in 2005. MarkPap Pacific LLC is a resident client of the Shady Grove Innovation Center in Rockville MD and is provided with legal and business development support within the Montgomery County Incubators Network. Moawad PC Law firm from Chevy Chase, MD provides legal services. Mr. Duc Duong was an Advisor for China market helping MarkPap Pacific LLC. BioSciCon, Inc. is a Corporate Partner of the Johns Hopkins University, Montgomery County Campus, where it receives business and legal support. Payroll and accountant services are provided by professional contractors. Business professionals constitute The MarkPap LLC Business Advisory Team, which is coordinated by Dr. Nenad Markovic, President and CEO of MarkPap LLC.

Acknowledgements

MarkPap Technology development has been supported in part by SBIR phases 1 and 2 grants from the National Institutes of Health, Bethesda, MD.We also acknowledge NIH support for business development through the NIH Commercialization Assistance Program (CAP) -- Dawnbreaker, Inc. (2003), Larta Instutue (2007), to foster further commercialization of BioSciCon products. Information about BioSciCon, Inc. and MarkPap® Technology appears on the NIH Web Site, Office of Technology Transfer and SBIR and STTR Success Story for BioSciCon, Inc.
Department for Economic Development, Montgomery County, MD provided a grant/loan to BioSciCon in the past. FDA, CDRH provided regulatory guidance.